Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
PRE-INTERVENTION GROUP COMPARISON INTERVENTION COMPLIANCE<br />
All 59 ptients took their medications daily for 14<br />
Baseline analysis showed that the two groups were days.<br />
comparable in the absence of exposure to immunotherapy,<br />
in demographic characteristics, in physical OUTCOME GROUP COMPARISONS<br />
examination and rhinos¢opic findings. Except for a<br />
significantly longer duration of seasonal allergic rhinitis I. Efficacy<br />
among those on loratadine, reveiw of medical hsitory A. The physicians' evaluation of signs and<br />
showed no other clinically important differences<br />
symptoms during the course of treatment was<br />
(Table I). compared between the two groups.<br />
TABLE 1: BASELINE GROUP COMPARISONS<br />
LORATADINE ASTEMIZOLE p VALUE<br />
Demographic<br />
1. meanage (yrs) 26.7 +-1 25.7+-1 0.13<br />
2. weight (ibs) 124.9+ol 21.9+4 0.64<br />
3. height (cm) 160.4+-11 60.0+-1 0.81<br />
4. male:female 16:13 17:13 (I.79<br />
MedicalHistory<br />
1. meandurationof 9.3+-1 5.2+-0 0.01<br />
seasonalallergic<br />
rhinitis(yrs)<br />
2. meannumberof episodes 7.2+-2 8.0+-2 0.74<br />
of seasonalallergic<br />
rNnitis<br />
3. meandurationof current 7.4+-2 7.5+-1 0.93<br />
episode(days)<br />
4. perennialallergic 20 (69%) 21 (70%) 0.95<br />
rhinitis<br />
Screeningrhinoscopyfindings:<br />
1, NASALMEMBRANE 25 (86%) 25 (83%) 0.97<br />
pale& boggy 4 (14%) 5 (17%)<br />
erythematous<br />
2. NASALPt,TENCY<br />
partiallyoccluded 27 (94%) 29 (97%) {I.49<br />
totallyoccluded 1 (3%) 1 (3%)<br />
normal 1 (3%) 0<br />
3. NASALSECRETIONS<br />
thinwatery 18 (62%) 19 (63%) 0.55<br />
mucoid 11 (38%) 10 (34%)<br />
4. QUANTITYOFNASAL<br />
SECRETIONS<br />
slightto moderate 17 (59%) 20 (67%) 0.54<br />
minimal 9 (31%) 7 (23%)<br />
copious 3 (10%) 2 (7%)<br />
none 0 1 (3%)<br />
69
Change language